David Maloney, M.D., Ph.D.
Fred Hutchinson Cancer Center, Cancer Cell Therapy
David G. Maloney, M.D., Ph.D., is Medical Director at the Fred Hutchinson Cancer Research Center Cellular Immunotherapy and the Bezos Family Immunotherapy Clinic, at the Seattle Cancer Care Alliance; and Professor of Medicine, Division of Oncology at the University of Washington. Dr. Maloney received his M.D. and Ph.D. in cancer biology from Stanford University, completed his internship and residency in internal medicine at Brigham and Woman’s Hospital, and a fellowship in oncology at Stanford. Dr. Maloney’s research interest is in the development of immunotherapies for lymphoma, myeloma, CLL, and ALL. He has had a long-standing interest in the mechanisms of action of monoclonal antibodies and the use of non-myeloablative allogeneic transplantation for the treatment of hematologic malignancies. Non-myeloablative conditioning has enabled many more patients to take advantage of the lifesaving potential of stem cell transplantation. For much of his career, Dr. Maloney has focused on developing and improving antibody-based therapies against blood cancers. He was instrumental in the development and testing of rituximab while working with Dr. Ron Levy at Stanford. Rituximab was the first antibody-based cancer drug on the market, and it has transformed treatment of certain leukemias and lymphomas. Currently, Dr. Maloney’s major interests are in the development of chimeric antigen receptor (CAR) T cell therapy for which he leads multiple clinical trials using this therapy for a variety of cancers.
Dr. Maloney has amassed greater than 200 publications in peer-reviewed journals in the areas of research described above. In 1993, the International Society for Biology Therapy of Cancer (now the Society for Immunotherapy of Cancer) conferred on Dr. Maloney its Presidential Award.